142 related articles for article (PubMed ID: 22483234)
41. p53 protein expression in nephroblastomas: a predictor of poor prognosis.
Govender D; Harilal P; Hadley GP; Chetty R
Br J Cancer; 1998; 77(2):314-8. PubMed ID: 9461003
[TBL] [Abstract][Full Text] [Related]
42. Mutations of p53 in Wilms' tumors.
Takeuchi S; Bartram CR; Ludwig R; Royer-Pokora B; Schneider S; Imamura J; Koeffler HP
Mod Pathol; 1995 Jun; 8(5):483-7. PubMed ID: 7675765
[TBL] [Abstract][Full Text] [Related]
43. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
[TBL] [Abstract][Full Text] [Related]
44. Bilateral Wilms' tumors: a single-center experience with 19 cases.
Millar AJ; Davidson A; Rode H; Numanoglu A; Hartley PS; Daubenton JD; Desai F
J Pediatr Surg; 2005 Aug; 40(8):1289-94. PubMed ID: 16080934
[TBL] [Abstract][Full Text] [Related]
45. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors.
Tabori U; Shlien A; Baskin B; Levitt S; Ray P; Alon N; Hawkins C; Bouffet E; Pienkowska M; Lafay-Cousin L; Gozali A; Zhukova N; Shane L; Gonzalez I; Finlay J; Malkin D
J Clin Oncol; 2010 Apr; 28(12):1995-2001. PubMed ID: 20308654
[TBL] [Abstract][Full Text] [Related]
46. Wilms' tumor 1991. Clinical evaluation and treatment.
Exelby PR
Urol Clin North Am; 1991 Aug; 18(3):589-97. PubMed ID: 1652172
[TBL] [Abstract][Full Text] [Related]
47. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
[TBL] [Abstract][Full Text] [Related]
48. Review of prognostic and predictive aspects of mutated TP53 in Wilms' tumor biology with morphological report and molecular analysis of 37-year-old man's nephroblastoma.
Wincewicz A; Kowalik A; Zięba S; Kopczyński J; Góźdź S; Sulkowski S
Pol J Pathol; 2016; 67(4):307-312. PubMed ID: 28547957
[TBL] [Abstract][Full Text] [Related]
49. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
[TBL] [Abstract][Full Text] [Related]
50. Clinical characteristics and outcome of Wilms tumors with a favorable histology in Japan: a report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan.
Suita S; Kinoshita Y; Tajiri T; Hara T; Tsuneyoshi M; Mizote H; Inada H; Takamatsu H; Kawano Y; Inomata Y; Nagasaki A; Ono Y; Handa N; Okamura J; Ishii E; Kawakami K;
J Pediatr Surg; 2006 Sep; 41(9):1501-5. PubMed ID: 16952581
[TBL] [Abstract][Full Text] [Related]
51. [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm].
Zhao SJ; Liu JY; Ren FR; Feng YJ
Zhonghua Fu Chan Ke Za Zhi; 2005 Apr; 40(4):264-8. PubMed ID: 15924676
[TBL] [Abstract][Full Text] [Related]
52. Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines.
Williams RD; Hing SN; Greer BT; Whiteford CC; Wei JS; Natrajan R; Kelsey A; Rogers S; Campbell C; Pritchard-Jones K; Khan J
Genes Chromosomes Cancer; 2004 Sep; 41(1):65-79. PubMed ID: 15236318
[TBL] [Abstract][Full Text] [Related]
53. Decrease in LDL receptor-related protein expression and function correlates with advanced stages of Wilms tumors.
Desrosiers RR; Rivard ME; Grundy PE; Annabi B
Pediatr Blood Cancer; 2006 Jan; 46(1):40-9. PubMed ID: 16106426
[TBL] [Abstract][Full Text] [Related]
54. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
Roberts DJ; Haber D; Sklar J; Crum CP
Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
[TBL] [Abstract][Full Text] [Related]
55. Pediatric genitourinary tumors.
Castellino SM; McLean TW
Curr Opin Oncol; 2007 May; 19(3):248-53. PubMed ID: 17414644
[TBL] [Abstract][Full Text] [Related]
56. Immunoexpression of SALL4 in Wilms tumors and developing kidney.
Deisch J; Raisanen J; Rakheja D
Pathol Oncol Res; 2011 Sep; 17(3):639-44. PubMed ID: 21258884
[TBL] [Abstract][Full Text] [Related]
57. PAX immunoreactivity patterns in anaplastic wilms tumors.
Fan R
Fetal Pediatr Pathol; 2014 Feb; 33(1):60-3. PubMed ID: 24245795
[TBL] [Abstract][Full Text] [Related]
58. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
Williams RD; Al-Saadi R; Natrajan R; Mackay A; Chagtai T; Little S; Hing SN; Fenwick K; Ashworth A; Grundy P; Anderson JR; Dome JS; Perlman EJ; Jones C; Pritchard-Jones K
Genes Chromosomes Cancer; 2011 Dec; 50(12):982-95. PubMed ID: 21882282
[TBL] [Abstract][Full Text] [Related]
59. The expression of IL-6 and STAT3 might predict progression and unfavorable prognosis in Wilms' tumor.
Zhang LJ; Liu W; Gao YM; Qin YJ; Wu RD
Biochem Biophys Res Commun; 2013 Jun; 435(3):408-13. PubMed ID: 23665320
[TBL] [Abstract][Full Text] [Related]
60. [Immunohistochemical expression of p53 oncoprotein in Wilms tumour in relation to histological components, histological types and preoperative chemotherapy].
Djuricić S; Djokić D; Vujić D; Basta-Jovanović G; Todorović V; Radojević-Skodrić S; Zdravković S; Vujanić GM
Srp Arh Celok Lek; 2008 Dec; 136 Suppl 4():298-306. PubMed ID: 20804099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
